140 related articles for article (PubMed ID: 38246352)
1. G protein-coupled estrogen receptor 1 ameliorates nonalcoholic steatohepatitis through targeting AMPK-dependent signaling.
Li L; Yao Y; Wang Y; Cao J; Jiang Z; Yang Y; Wang H; Ma H
J Biol Chem; 2024 Mar; 300(3):105661. PubMed ID: 38246352
[TBL] [Abstract][Full Text] [Related]
2. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
3. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
4. Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model.
Guzman S; Dragan M; Kwon H; de Oliveira V; Rao S; Bhatt V; Kalemba KM; Shah A; Rustgi VK; Wang H; Bech PR; Abbara A; Izzi-Engbeaya C; Manousou P; Guo JY; Guo GL; Radovick S; Dhillo WS; Wondisford FE; Babwah AV; Bhattacharya M
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35349482
[TBL] [Abstract][Full Text] [Related]
5. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
6. Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet.
Baiges-Gaya G; Fernández-Arroyo S; Luciano-Mateo F; Cabré N; Rodríguez-Tomàs E; Hernández-Aguilera A; Castañé H; Romeu M; Nogués MR; Camps J; Joven J
J Nutr Biochem; 2021 Mar; 89():108559. PubMed ID: 33264665
[TBL] [Abstract][Full Text] [Related]
7. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
8. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
[TBL] [Abstract][Full Text] [Related]
9. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.
Lan T; Yu Y; Zhang J; Li H; Weng Q; Jiang S; Tian S; Xu T; Hu S; Yang G; Zhang Y; Wang W; Wang L; Zhu Q; Rong X; Guo J
Hepatology; 2021 Aug; 74(2):686-703. PubMed ID: 33576035
[TBL] [Abstract][Full Text] [Related]
10. Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase.
Oh E; Lee J; Cho S; Kim SW; Won K; Shin WS; Gwak SH; Ha J; Jeon SY; Park JH; Song IS; Thoudam T; Lee IK; Kim S; Choi SY; Kim KT
Mol Pharmacol; 2023 Nov; 104(5):214-229. PubMed ID: 37595967
[TBL] [Abstract][Full Text] [Related]
11. Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice.
Sun H; Seok S; Jung H; Kemper B; Kemper JK
Mol Metab; 2022 Dec; 66():101603. PubMed ID: 36126896
[TBL] [Abstract][Full Text] [Related]
12. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
13. The role of AMPKα2 in the HFD-induced nonalcoholic steatohepatitis.
Zhang X; Liu S; Zhang C; Zhang S; Yue Y; Zhang Y; Chen L; Yao Z; Niu W
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165854. PubMed ID: 32502647
[TBL] [Abstract][Full Text] [Related]
14. A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway.
Wang L; Dong W; Gao H; Chen C; Liang S; Ye X; Liu Y; Hou Y; Fan L; Pan T; Wang Z; Chen Y; Luo Y; Song L
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166560. PubMed ID: 36167161
[TBL] [Abstract][Full Text] [Related]
15. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
16. Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Baek JH; Kim MS; Jung HR; Hwang MS; Lee CH; Han DH; Lee YH; Yi EC; Im SS; Hwang I; Kim K; Chung JY; Chun KH
Exp Mol Med; 2023 Jul; 55(7):1520-1530. PubMed ID: 37394587
[TBL] [Abstract][Full Text] [Related]
17. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
18. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
[TBL] [Abstract][Full Text] [Related]
19. [Research progress on AMPK activation in nonalcoholic fatty liver disease].
Ye XY; Li TX; Huang ZW; Fu WW; Li Q
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1220-1223. PubMed ID: 38238958
[TBL] [Abstract][Full Text] [Related]
20. Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases.
Dewidar B; Mastrototaro L; Englisch C; Ress C; Granata C; Rohbeck E; Pesta D; Heilmann G; Wolkersdorfer M; Esposito I; Reina Do Fundo M; Zivehe F; Yavas A; Roden M
EBioMedicine; 2023 Aug; 94():104714. PubMed ID: 37454552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
